Key result
Valsartan-loaded mixed micelles increase oral bioavailability ~4-fold vs suspension, reducing oxidative stress and cardiac injury.
Why the study?
Valsartan-loaded mixed micelles had not been elaborated and their impact on Mhrt/Nrf2 and Trx1 pathways had not yet been inspected.
Does valsartan-loaded mixed micelles improve oral bioavailability and cardioprotection in rats with cisplatin-induced cardiotoxicity compared to valsartan suspension?
Does valsartan-loaded mixed micelles improve oral bioavailability and cardioprotection in rats with cisplatin-induced cardiotoxicity compared to valsartan suspension?
Valsartan-loaded mixed micelles significantly improved oral bioavailability and enhanced cardioprotection against cisplatin-induced cardiotoxicity in rats compared to standard valsartan suspension.
Answers are grounded in this paper and cite their sources.
Should not change practice; leaves open translation of micellar valsartan to human cardioprotection.
This study aimed to develop valsartan (VAL)-loaded mixed micelles and investigate their cardioprotective potential and molecular mechanisms through Mhrt/Nrf2 and Trx1 pathways. VAL-loaded mixed micelles have not been elaborated and their impact on Mhrt/Nrf2 and Trx1 pathways has not been yet inspected. VAL-loaded mixed micelles were prepared, incorporating Pluronic F127 and Tween 80, adopting thin-film hydration method. The micelles were evaluated for drug entrapment efficiency, loading characteristics, particle size, morphology, in vitro drug release and micelles storage stability. The pharmacokinetic studies were explored in rats. Also, VAL suspension and mixed micelles were tested in cisplatin-induced cardiotoxicity in rats either pre to or simultaneously with cisplatin. RNA expression of lnc Mhrt and protein expression of Nrf2, Trx1, Ask1, AMPK and caspase 3, oxidative stress and cardiac injury markers besides tailed DNA% by comet assay were assessed. Pharmacokinetic studies evoked a 3.75-fold increase in oral bioavailability as compared with VAL suspension. Overall, treatment with VAL-loaded mixed micelles was superior to VAL suspension in decreasing oxidative stress and cardiac injury markers and restoring the abnormalities occurred in Mhrt/Nrf2 and Trx1 pathways. Thus, mixed micelles would be promising nanocarrier for the engineering of VAL with reinforced pharmacokinetics and cardioprotection characteristics.
No takes yet. Share an insight, caveat, or question.
Mahmoud et al. (2019) studied Cisplatin-induced cardiotoxicity. Valsartan-loaded mixed micelles vs. Valsartan suspension was evaluated on Oral bioavailability and cardioprotection markers (3.75-fold increase in oral bioavailability). Valsartan-loaded mixed micelles evoked a 3.75-fold increase in oral bioavailability compared with valsartan suspension and were superior in decreasing oxidative stress and cardiac injury markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: